Stocks · News reference
Maxim Group Maintains Buy on Context Therapeutics, Lowers Price Target to $4
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Why SiTime Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
SiTime Corp (SITM) stock rose 30.7% in pre-market trading after beating earnings and sales estimates. Other gainers include CLRO, WYHG, SURG, PAVS, MGRX, CELZ, SOUN, WPP, HNST. YXT was the only loser after CFO resignation.
Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move
Context Therapeutics stock fell after hours as Q2 loss widened and the company prioritized its pipeline.
Context Therapeutics Q2 EPS $(0.15) Misses $(0.09) Estimate
Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.09) by 66.67 percent. This is a 66.67 percent decrease over losses of $(0.09) per